SKLB1028 is a novel orally bioavailable multikinase inhibitor of EGFR, FLT3 and Abl. SKLB1028 exhibits exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. References: Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26(8):1892-5. doi: 10.1038/leu.2012.67. Epub 2012 Mar 9. PubMed PMID: 22402607.

纯度：≥98%

CAS：1350544-93-2